OBJECTIVE: This study aimed to evaluate the clinical efficacy of labetalol (LBT) combined with magnesium sulfate (MgSO4) in improving symptoms and pregnancy outcomes in patients with hypertensive disorders of pregnancy (HDP). METHODS: A total of 122 HDP patients admitted between January 2020 and June 2024 were included. Among them, 56 patients (control group) received MgSO4 alone, while 66 patients (research group) received a combination of LBT and MgSO4. Comparative analyses were conducted to evaluate therapeutic effectiveness, symptom improvement (edema, hypertension, and proteinuria), brain-related symptoms (nausea and vomiting, sluggishness, blurred vision, dizziness, and headache), pregnancy outcomes (placental abruption, neonatal asphyxia, fetal distress, and postpartum hemorrhage), blood pressure indicators (systolic (SBP) and diastolic blood pressure (DBP)), fetal umbilical artery hemodynamics (systolic-to-diastolic flow velocity ratio (S/D) and pulsatility index (PI)), and high-sensitivity C-reactive protein (hs-CRP). RESULTS: The research group demonstrated significantly better outcomes than the control group, including a higher overall therapeutic effectiveness rate, faster resolution of edema, hypertension, and proteinuria, a lower incidence of adverse pregnancy events, and more pronounced reductions in SBP, DBP, S/D, PI, and hs-CRP levels after treatment (all P < 0.05). CONCLUSION: The combination of LBT and MgSO4 is highly effective in improving symptoms and pregnancy outcomes in HDP patients, outperforming MgSO4 monotherapy. This approach has strong potential for broader clinical application.